THIRD RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 19th, 2009 • Talecris Biotherapeutics Holdings Corp. • Pharmaceutical preparations • North Carolina
Contract Type FiledAugust 19th, 2009 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT between Talecris Biotherapeutics Holdings Corporation (the “Company”) and Lawrence D. Stern (the “Executive”) (together, the “Parties”) was effective as of April 1, 2005 (the “Effective Date”) and was amended and restated as of April 1, 2007 (the “Original Restatement Date”), with all terms retroactive to such date, was hereby amended and restated as of January 1, 2009, and is hereby further amended and restated as of April 1, 2009 (the “Third Restatement Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 19th, 2009 • Talecris Biotherapeutics Holdings Corp. • Pharmaceutical preparations • North Carolina
Contract Type FiledAugust 19th, 2009 Company Industry JurisdictionEMPLOYMENT AGREEMENT (as amended and restated herein, the “Agreement”), originally entered into as of January 21, 2008 and now amended and restated as of November 26, 2008 between Talecris Biotherapeutics Holdings Corporation (the “Company”) and Kari Heerdt (the “Executive”) (together, the “Parties”).
EMPLOYMENT AGREEMENTEmployment Agreement • July 2nd, 2009 • Talecris Biotherapeutics Holdings Corp. • Pharmaceutical preparations • North Carolina
Contract Type FiledJuly 2nd, 2009 Company Industry JurisdictionEMPLOYMENT AGREEMENT (“Agreement”) dated as of September 05, 2006 and amended and restated as of September 5, 2008 (“Renewal Date”), between Talecris Biotherapeutics Holdings Corp. (the “Company”) and John F. Gaither, Jr. (the “Executive”) (together, the “Parties”) is amended and restated as of November 6, 2008.
EMPLOYMENT AGREEMENTEmployment Agreement • July 2nd, 2009 • Talecris Biotherapeutics Holdings Corp. • Pharmaceutical preparations • North Carolina
Contract Type FiledJuly 2nd, 2009 Company Industry JurisdictionEMPLOYMENT AGREEMENT (Agreement”) dated as of September 14, 2005 and amended and restated as of October 10, 2008 between Talecris Biotherapeutics Holdings Corp. (the “Company”) and John M. Hanson (the “Executive”) (together, the “Parties”).